Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria (PREGACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00852423|
Recruitment Status : Completed
First Posted : February 27, 2009
Last Update Posted : March 14, 2016
|Condition or disease||Intervention/treatment||Phase|
|Malaria in Pregnancy||Drug: Dihydroartemisinin-piperaquine Drug: Artesunate-mefloquine Drug: Artesunate-amodiaquine Drug: Artemether-lumefantrine||Phase 3|
Malaria is the most important human parasitic disease. Although pregnant women are a high-risk group, they are almost systematically excluded from clinical trials, for fear of teratogenicity and embryotoxicity; thus, we generally lack sufficient information on the safety and efficacy of most antimalarials in pregnancy, as well as evidence-based recommendations for the prevention and treatment of malaria during pregnancy.
The WHO recommendation to use artemisinin combination therapy (ACT) in the 2nd and 3rd trimester is already implemented in several African countries. However, the documentation of their efficacy and safety in pregnancy is still limited, especially concerning the African contexts.
Therefore, we propose to test 4 fixed-dose combinations (artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine), to evaluate their efficacy and safety when administered to pregnant women (2nd and 3rd trimester) infected with P. falciparum. Explanatory variables will be collected for treatment failure (PCR-corrected) and for recurrent parasitaemia. The primary hypothesis tested will be the clinical equivalence (pair-wise non-inferiority) of the 4 treatment regimens with clinical equivalence defined as difference in treatment failure rates (PCR corrected) of 5% or less.
In addition, an attempt will be done to carry out in vitro testing at the time of recurrent infection. However, the success of the test will depend on the parasite density. In addition, blood samples collected on filter paper at day 0 and at day of recurrent parasitaemia will be genotyped for the search of known molecular markers related to drug resistance. Not all samples will be analyzed; rather these will be selected according to the therapeutic response so that the prevalence of molecular markers will be compared between treatment successes, true treatment failures and new infections.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3428 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria|
|Study Start Date :||June 2010|
|Primary Completion Date :||October 2013|
|Study Completion Date :||April 2015|
Three-day treatment with dihydroartemisinin-piperaquine
DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
Other Name: DHAPQ, Eurartesim
Three-day treatment with mefloquine artesunate
MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
Other Name: MQAS
Active Comparator: AQAS
Three-day treatment with artesunate-amodiaquine
AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
Other Name: AQAS, artesunate-amodiaquine Winthrop®
Active Comparator: AL
Three day treatment with artemether-lumefantrine (Coartem(R)
AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
Other Name: AL, Coartem, Riamet
- Treatment Failure (PCR adjusted) [ Time Frame: Day 63 ]
- Safety profiles including significant changes in relevant laboratory values [ Time Frame: Until delivery ]
- Time to failure [ Time Frame: Case by case ]
- PCR unadjusted treatment failure [ Time Frame: Day 63 ]
- Gametocyte carriage (gametocyte-weeks) [ Time Frame: Case by case ]
- Asexual parasite clearance time [ Time Frame: Days to 2 consecutive negative blood slides. ]
- Gametocytaemia (prevalence and density) [ Time Frame: Day 7, 14, 21, 28 and 63 after treatment ]
- Haemoglobin changes [ Time Frame: Days 14, 28, 42 and 63 ]
- The presence of acute, chronic or past infection of the placenta (prevalence) [ Time Frame: Delivery ]
- Mean birth weight and prevalence of low birth weight newborns [ Time Frame: Delivery ]
- In vitro vitro and search of molecular markers related to drug resistance [ Time Frame: At the time of recurrent infection ]
- Determination of the PK profile of MQ, AQ and PQ (on 120 women/treatment) [ Time Frame: Case by case ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00852423
|Nanoro, Burkina Faso|
|Nazoanga, Burkina Faso|
|Kwame Nkrumah University of Science & Technology, Kumasi|
|Ejisu Sekyere East, Ashanti Region, Ghana|
|Kwame Nrumah University of Science and Technology, Kumasi|
|Juaben Government Hospital, Ashanti Region, Ghana|
|Effiduase Government Hospital|
|College of Medicine, University of Malawi|
|Chikwawa District Hospital, Blantyre, Malawi|
|St Paul Hospital|
|Nchelenge, Nchelenge District, Zambia|
|Study Chair:||Umberto D'Alessandro, MD||Institute Tropical Medicine Belgium and MRC Unit in The Gambia|
|Principal Investigator:||Tinto Halidou, PharmD||Centre Muraz|